Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

If there were any realistic chance that there

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
arvitar Member Profile
Followed By 52
Posts 13,286
Boards Moderated 0
Alias Born 01/19/09
160x600 placeholder
NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the Unive... PR Newswire (US) - 3/19/2018 11:12:00 AM
NanoViricides Files Quarterly Report for Period Ending December 31, 2017 PR Newswire (US) - 2/21/2018 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/20/2018 1:55:19 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/14/2018 5:57:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2017 10:29:10 AM
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates PR Newswire (US) - 12/6/2017 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/22/2017 4:23:23 PM
NanoViricides Files Quarterly Report for Period Ending September 30, 2017 PR Newswire (US) - 11/20/2017 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2017 5:25:18 PM
Revised Proxy Soliciting Materials (definitive) (defr14a) Edgar (US Regulatory) - 11/8/2017 5:18:02 PM
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November ... PR Newswire (US) - 11/6/2017 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/27/2017 6:08:02 AM
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Cente... PR Newswire (US) - 10/26/2017 7:00:00 AM
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of th... PR Newswire (US) - 10/17/2017 7:00:00 AM
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials PR Newswire (US) - 9/29/2017 7:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 9/28/2017 4:51:22 PM
NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference... PR Newswire (US) - 9/11/2017 9:04:00 AM
NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin PR Newswire (US) - 7/10/2017 7:00:00 AM
NanoViricides' Poster "Novel NanoviricidesĀ® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented... PR Newswire (US) - 6/26/2017 9:00:00 AM
NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology PR Newswire (US) - 6/20/2017 7:00:00 AM
NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York... PR Newswire (US) - 6/13/2017 7:00:00 AM
NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell ... PR Newswire (US) - 6/6/2017 5:30:00 PM
NanoViricides Files Quarterly Report for Period Ending 2017-03-31 PR Newswire (US) - 5/16/2017 7:50:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2017 5:03:04 PM
NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Compan... PR Newswire (US) - 4/26/2017 5:00:00 PM
arvitar   Thursday, 03/08/18 09:58:46 PM
Re: Nanotoday post# 138140
Post # of 138224 
If there were any realistic chance that there would be a positive development or news in the next 13 months, does anyone think Seymour would have left?

This seems painfully obvious, but Seymour's departure is being celebrated as positive progress. Some even believe that "we're going to be slowly trending up now that changes are in the works. "

It was even more glaringly obvious back in 2005 that Diwan and Seymour never believed there was value in any of this. They would have wanted all the resources directly applied towards developing drug candidates had they really believed in it. Instead, they built generational wealth for their families by siphoning off tens of millions of dollars through Theracour.

Yet, there are still investors who truly believe Diwan and Seymour believed their own bullshit at the start. Go figure.

A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist